Proteomics

Dataset Information

0

Myxopyronin B inhibits growth of a Fidaxomicin-resistant Clostridioides difficile isolate and interferes with toxin synthesis


ABSTRACT: Fidaxomicin is considered the current gold standard antibiotic for treating Clostridioides difficile infections and kills bacterial cells by inhibition of the RNA polymerase through binding to its switch region. Although binding sites do not overlap, also Myxopyronin B inhibits the RNA polymerase by binding its switch region. The here presented data prove that there is no cross-resistance between Fidaxomicin and Myxopyronin B in a Fidaxomicin-resistant C. difficile strain. Moreover, comparative LC-MS/MS analyses of Fidaxomicin, Myxopyronin B and Rifaximin stress in C. difficile strain 630 revealed that Myxopyronin B is able to suppress early phase toxin synthesis in C. difficile to the same degree as Fidaxomicin. Conclusively, Myxopyronin B is proposed as lead structure for the design of novel antibiotics for the therapy of C. difficile infections.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Peptoclostridium Difficile (strain 630) (clostridium Difficile)

SUBMITTER: Daniela Zuehlke  

LAB HEAD: Susanne Sievers

PROVIDER: PXD027366 | Pride | 2021-12-21

REPOSITORIES: Pride

Dataset's files

Source:
Action DRS
210407_HF2_DZ_MB_D1_1-5.raw Raw
210407_HF2_DZ_MB_D1_2-6.raw Raw
210407_HF2_DZ_MB_D1_3-7.raw Raw
210407_HF2_DZ_MB_D1_4-8.raw Raw
210407_HF2_DZ_MB_Rif1_1-5.raw Raw
Items per page:
1 - 5 of 50

Similar Datasets

2022-08-04 | PXD029250 | Pride
2023-03-29 | PXD029243 | Pride
2024-02-02 | PXD041951 | Pride
2023-03-20 | PXD039809 | Pride
2024-03-27 | PXD047097 | Pride
2017-03-06 | PXD005224 | Pride
2021-07-12 | PXD022830 | Pride
2019-01-18 | E-MTAB-7605 | biostudies-arrayexpress
2020-05-26 | PXD012030 | Pride
2020-07-31 | E-MTAB-8065 | biostudies-arrayexpress